Osteosarcoma
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Osteosarcoma is a highly competitive landscape with 121 programs across 53 companies. The most active players are Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., Biogen, Horizon Therapeutics Ireland DAC. 4 therapies are approved with 12 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
1 program
Biogen
1 program
Horizon Therapeutics Ireland DAC
1 program
Johnson & Johnson
1 program
Arog Pharmaceuticals, Inc.
1 program
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
84%
Small molecule
111 of 132 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 132 classified programs, each share of the total. Modality classified for 99% of 136 pipeline programs.
Analysis
Trial Status
120
clinical trials
Clinical Trials
Trial Activity
120 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)